Enveric Biosciences, a biotechnology company focused on neuroplastogen development, announced the issuance of five additional US patents and allowance of three patent applications for its EVM301 portfolio.
The new patents (Nos. 11,845,727, 11,858,895, 11,891,359, 11,998,557, and 12,128,058) bring the total number of issued US patents covering the company's EVM301 portfolio and drug candidate library to nine.
CEO Dr. Joseph Tucker states that the expanded patent portfolio covers a broad range of tryptamine derivative molecules, including carboxylated, aminated, prenylated, glycosylated, nitrilated, and halogenated derivatives.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.